US · IRWD
Ironwood Pharmaceuticals, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Boston, MA 02110
- Website
- ironwoodpharma.com
Price · as of 2025-12-31
$4.44
Market cap 556.36M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $50.49 | +1,037.16% |
| Intrinsic Value(DCF) | $1.43 | -67.79% |
| Graham-Dodd Method(GD) | $0.40 | -90.95% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $11.31 | $32.75 | $75.16 | $0.00 | $0.00 |
| 2012 | $13.79 | $44.08 | $22,727.24 | $0.00 | $0.00 |
| 2013 | $11.62 | $27.41 | $0.00 | $0.00 | $171.86 |
| 2014 | $12.62 | $48.79 | $1,115.70 | $0.00 | $0.00 |
| 2015 | $9.08 | $38.63 | $9,395.38 | $0.00 | $0.00 |
| 2016 | $14.55 | $42.14 | $81,439.51 | $0.00 | $0.00 |
| 2017 | $12.77 | $26.98 | $558.05 | $0.00 | $0.00 |
| 2018 | $11.13 | $27.92 | $2.45 | $0.00 | $0.00 |
| 2019 | $12.23 | $35.87 | $15.23 | $0.09 | $4.23 |
| 2020 | $11.32 | $38.37 | $4.80 | $3.72 | $0.00 |
| 2021 | $11.67 | $39.35 | $7.53 | $20.02 | $45.80 |
| 2022 | $10.67 | $85.60 | $4.02 | $9.90 | $8.35 |
| 2023 | $9.01 | $22.67 | $0.00 | $0.00 | $0.00 |
| 2024 | $1.50 | $30.85 | $0.00 | $0.00 | $0.00 |
| 2025 | $3.57 | $50.49 | $0.05 | $0.40 | $0.00 |
AI valuation
Our deep-learning model estimates Ironwood Pharmaceuticals, Inc.'s (IRWD) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $50.49
- Current price
- $4.44
- AI upside
- +1,037.16%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$1.43
-67.79% upside
Graham-Dodd
$0.40
-90.95% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| IRWD | Ironwood Pharmaceuticals,… | $4.44 | 556.36M | +1,037% | -68% | -91% | — | 24.11 | -10.55 | 1.96 | 5.51 | 0.21 | -10.18 | 99.36% | 40.10% | 8.11% | -13.49% | 62.48% | 6.42% | -3.88 | 3.63 | 1.13 | 1.08 | -0.03 | 1171818.00% | -1572.00% | 2283.00% | 21.93% | 0.52 | 167.05% | 0.00% | 0.00% | 88.68% | 4.85 | 4.54 | 1.95 | 2.60 |
| ACB | Aurora Cannabis Inc. | $3.84 | 217.76M | +498% | -40% | +80% | -82% | 27.82 | 0.78 | 1.28 | 6.97 | — | 0.92 | 54.65% | 1.44% | 0.46% | 2.80% | 0.80% | 1.87% | 0.18 | 0.59 | 4.31 | 2.06 | -1.56 | -10223.00% | 2701.00% | -9666.00% | -0.65% | 0.15 | -0.59% | 0.00% | 0.00% | 0.12% | 72.30 | -125.35 | 1.04 | -8.43 |
| ALDX | Aldeyra Therapeutics, Inc… | $5.46 | 328.49M | — | — | — | — | 0.00 | 0.00 | — | 1.55 | — | 0.00 | 0.00% | — | — | -152.98% | 0.00% | -93.94% | 0.35 | -18.51 | 2.58 | 2.52 | 1.55 | -4043.00% | — | 7717335287.00% | -9879606.86% | -1.20 | 649.97% | 0.00% | 0.00% | 16150447.97% | 1545737.39 | 1.63 | — | -8.67 |
| BIOA | BioAge Labs, Inc. | $22.27 | 798.49M | — | — | — | — | -0.69 | 0.15 | — | 4.33 | — | 0.15 | 0.00% | — | — | -94.98% | 95.18% | -37.02% | 0.03 | -33.04 | 12.86 | 12.76 | 5.04 | -2246.00% | — | 3826.00% | -106.31% | -1.85 | 63.16% | 0.00% | 0.00% | 772.94% | 3.80 | 5.72 | — | 0.23 |
| CGC | Canopy Growth Corporation | $1.12 | 576.26M | +725% | -39% | — | +204% | -0.42 | 0.52 | 0.95 | -0.99 | — | 0.72 | 29.56% | -43.55% | -222.35% | -122.35% | -14.04% | -54.48% | 0.72 | -1.57 | 3.12 | 1.95 | -0.49 | -3709.00% | -947.00% | -3809.00% | -69.30% | -1.76 | -21.21% | 0.00% | 0.00% | 102.99% | -4.03 | -2.67 | 1.76 | -16.18 |
| CLLS | Cellectis S.A. | $3.88 | 389.18M | +21,055% | +605% | — | — | -3.10 | 0.87 | 2.74 | 5.83 | — | 0.87 | 77.88% | -143.48% | -88.57% | -34.02% | 165.71% | -10.22% | 0.70 | -7.99 | 1.73 | 1.70 | 5.47 | -7684.00% | 539748.00% | -17562.00% | 17.18% | 0.13 | -54.33% | 0.00% | 0.00% | 0.12% | 0.93 | -2.83 | -1.33 | -0.96 |
| GNLX | Genelux Corporation | $2.98 | 112.1M | +972% | — | — | +2,543% | -4.42 | 5.03 | 16511.63 | -3.56 | — | 5.03 | -11187.50% | -396200.00% | -373362.50% | -130.58% | 1604.05% | -95.41% | 0.07 | — | 4.57 | 4.48 | 0.23 | -1810.00% | -9529.00% | 145.00% | -16.36% | -3.08 | 1093.57% | 0.00% | 0.00% | 0.00% | -3.25 | -4.77 | 12883.26 | -2.91 |
| LFCR | Lifecore Biomedical, Inc. | $7.20 | 269.76M | +1,115% | -61% | — | — | -6.29 | 182.17 | 1.89 | -41.53 | — | -14.53 | 31.27% | -13.38% | -30.04% | -612.08% | -13.25% | -15.70% | 97.92 | -0.79 | 2.84 | 1.72 | -13.91 | -48485.00% | 47.00% | -2490.00% | -5.60% | -0.01 | -10.46% | 0.00% | 0.00% | 1.05% | -21.22 | -26.87 | 2.84 | -0.01 |
| NPCE | NeuroPace, Inc. | $14.58 | 485.63M | +102% | +40% | — | — | -11.80 | 39.98 | 4.01 | -20.57 | — | 39.98 | 73.94% | -27.12% | -33.97% | -189.35% | -78.53% | -26.83% | 9.15 | -2.46 | 5.37 | 4.33 | -3.61 | -2677.00% | 2214.00% | -815.00% | -5.70% | -1.18 | -66.15% | 0.00% | 0.00% | 0.00% | -15.73 | -18.68 | 4.27 | -4.71 |
| SLN | Silence Therapeutics plc | $5.44 | 256.95M | +597% | -16% | — | — | -2.07 | 0.56 | 1.73 | 1.48 | — | 0.60 | 72.70% | -146.38% | -104.74% | -46.39% | 212.32% | -22.47% | 0.00 | — | 11.14 | 10.36 | 2.47 | -3190.00% | 7047.00% | 7223.00% | -90.74% | -4.02 | 227.52% | 0.00% | 0.00% | 70.57% | 1.14 | 1.07 | -1.67 | -2.43 |
| TKNO | Alpha Teknova, Inc. | $2.58 | 138.11M | +974% | -63% | — | — | -7.38 | 1.85 | 3.14 | -13.45 | — | 2.24 | 33.17% | -41.90% | -42.59% | -22.83% | -21.20% | -15.52% | 0.22 | -23.91 | 4.58 | 1.40 | -0.91 | -4386.00% | 735.00% | -3170.00% | -7.25% | -1.07 | -11.53% | 0.00% | 0.00% | 13.58% | -8.04 | -14.79 | 3.37 | 0.52 |
About Ironwood Pharmaceuticals, Inc.
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
- CEO
- Thomas A. McCourt
- Employees
- 253
- Beta
- 0.19
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($1.43 ÷ $4.44) − 1 = -67.79% (DCF, example).